Appili Therapeutics Inc Class A (APLI) Price & Analysis

Compare

25 Followers

APLI Stock Chart & Stats

Day’s Range― - ―

52-Week RangeC$0.01 - C$0.05

Previous CloseN/A

Volume36.33K

Average Volume (3M)28.79K

Market Cap

$1.82M

Enterprise ValueC$13.05M

Total Cash (Recent Filing)$1.23M

Total Debt (Recent Filing)$12.29M

Price to Earnings (P/E)―

Beta0.67

Next Earnings

Nov 13, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding121,266,120

10 Day Avg. Volume13,255

30 Day Avg. Volume28,791

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap7.17

Enterprise Value/Revenue129.88

Enterprise Value/Gross Profit140.27

Enterprise Value/Ebitda36.18

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering1

Appili Therapeutics Inc Class A News

Appili Therapeutics, colleagues publish manuscript on ATI-1701 efficacy

Appili Therapeutics (APLIF) announced a new publication in the journal Vaccine, supporting the efficacy of its biodefense vaccine...

12d ago

Appili Therapeutics Strengthens Biodefense Partnerships and Advances Drug Development

Appili Therapeutics Inc Class A ( ($TSE:APLI) ) has issued an announcement. Appili Therapeutics has reported its financial...

3d ago

Appili Therapeutics Demonstrates Efficacy of Tularemia Vaccine Candidate

Appili Therapeutics Inc Class A ( ($TSE:APLI) ) has issued an update. Appili Therapeutics announced a peer-reviewed publication...

12d ago

Appili Therapeutics Advances Infectious Disease Solutions with LIKMEZ Re-launch and Vaccine Developments

The latest announcement is out from Appili Therapeutics Inc Class A ( ($TSE:APLI) ). Appili Therapeutics has re-launched...

2M ago

Appili Therapeutics Ends Agreement with Aditxt, Secures Loan Extensions

Appili Therapeutics Inc Class A ( ($TSE:APLI) ) has issued an update. Appili Therapeutics announced the formal termination...

3M ago

Appili Therapeutics Faces Termination of Agreement with Aditxt

An announcement from Appili Therapeutics Inc Class A ( ($TSE:APLI) ) is now available. Appili Therapeutics announced that...

3M ago

Aditxt announces termination of arrangement agreement with Appili Therapeutics

Aditxt (ADTX) announced that it has determined it is in the best interest of the company and its...

3M ago

ADTX

Appili Therapeutics Advances Tularemia Vaccine Research

Appili Therapeutics Inc Class A ( ($TSE:APLI) ) has issued an announcement. Appili Therapeutics announced the publication of...

4M ago

Appili Therapeutics publishes manuscript on emergency response to tularemia

Appili Therapeutics (APLIF) announced a publication in the journal Frontiers in Bacteriology on the prevention of tularemia, a...

4M ago

Appili Therapeutics Secures New Patents for LIKMEZ, Strengthening Market Position

Appili Therapeutics Inc Class A ( ($TSE:APLI) ) just unveiled an update. Appili Therapeutics has announced the granting...

4M ago

Appili Therapeutics granted new patents for LIKMEZ

Appili Therapeutics (APLIF) announced the United States Patent and Trademark Office and the Mexican Patent Office have granted...

4M ago

Appili Therapeutics CEO to Discuss Strategic Growth and Funding Initiatives

Appili Therapeutics Inc Class A ( ($TSE:APLI) ) has issued an update. Appili Therapeutics announced that its CEO,...

5M ago

Appili Therapeutics CEO to join Aditxt CEO for weekly update on April 4

Appili Therapeutics (APLIF) announced that its President and CEO, Don Cilla, will join Aditxt (ADTX) Co-founder and CEO,...

5M ago

ADTX

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

5M ago

PLX

SLS

APLI FAQ

What was Appili Therapeutics Inc Class A’s price range in the past 12 months?

Appili Therapeutics Inc Class A lowest stock price was C$0.01 and its highest was C$0.04 in the past 12 months.

What is Appili Therapeutics Inc Class A’s market cap?

Appili Therapeutics Inc Class A’s market cap is $1.82M.

When is Appili Therapeutics Inc Class A’s upcoming earnings report date?

Appili Therapeutics Inc Class A’s upcoming earnings report date is Nov 13, 2025 which is in 88 days.

How were Appili Therapeutics Inc Class A’s earnings last quarter?

Appili Therapeutics Inc Class A released its earnings results on Aug 14, 2025. The company reported -C$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.01.

Is Appili Therapeutics Inc Class A overvalued?

According to Wall Street analysts Appili Therapeutics Inc Class A’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Appili Therapeutics Inc Class A pay dividends?

Appili Therapeutics Inc Class A does not currently pay dividends.

What is Appili Therapeutics Inc Class A’s EPS estimate?

Appili Therapeutics Inc Class A’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Appili Therapeutics Inc Class A have?

Appili Therapeutics Inc Class A has 121,266,120 shares outstanding.

What happened to Appili Therapeutics Inc Class A’s price movement after its last earnings report?

Appili Therapeutics Inc Class A reported an EPS of -C$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Appili Therapeutics Inc Class A?

Currently, no hedge funds are holding shares in TSE:APLI

Company Description

Appili Therapeutics Inc Class A

Appili Therapeutics Inc Class A (APLI) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for infectious diseases and other unmet medical needs. Based in Canada, the company specializes in drug development aimed at addressing significant health challenges such as antibiotic-resistant infections and other critical diseases. Appili's core products and services include a pipeline of drug candidates in various stages of clinical development, targeting both strategic partnerships and regulatory approvals to advance its mission.

Appili Therapeutics Inc Class A (APLI) Earnings & Revenues

Historic Earnings Reports

APLI Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"NaN":"―"}},"plotLines":[{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[null,null,null,null,null],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2021","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.02,0.018461538461538463,0.016923076923076923,0.015384615384615385,0.013846153846153847,0.012307692307692308,0.01076923076923077,0.009230769230769232,0.007692307692307693,0.006153846153846154,0.004615384615384615,0.003076923076923078,0.0015384615384615406,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.02,"date":1612137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.81,"date":1627776000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1633046400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.77,"date":1635724800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.115,"date":1640995200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.125,"date":1643673600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.033,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.035,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.035,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.035,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.03,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.015,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >